203 related articles for article (PubMed ID: 37153618)
1. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Rabia E; Garambois V; Dhommée C; Larbouret C; Lajoie L; Buscail Y; Jimenez-Dominguez G; Choblet-Thery S; Liaudet-Coopman E; Cerutti M; Jarlier M; Ravel P; Gros L; Pirot N; Thibault G; Zhukovsky EA; Gérard PE; Pèlegrin A; Colinge J; Chardès T
Front Immunol; 2023; 14():1168444. PubMed ID: 37153618
[TBL] [Abstract][Full Text] [Related]
2. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
3. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
4. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
6. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
7. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
Grugan KD; Dorn K; Jarantow SW; Bushey BS; Pardinas JR; Laquerre S; Moores SL; Chiu ML
MAbs; 2017 Jan; 9(1):114-126. PubMed ID: 27786612
[TBL] [Abstract][Full Text] [Related]
8. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
10. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
12. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
13. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
14. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
[TBL] [Abstract][Full Text] [Related]
15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
16. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.
Seifert O; Rau A; Beha N; Richter F; Kontermann RE
MAbs; 2019 Jul; 11(5):919-929. PubMed ID: 30951400
[TBL] [Abstract][Full Text] [Related]
17. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
[TBL] [Abstract][Full Text] [Related]
18. Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.
Geuijen CAW; De Nardis C; Maussang D; Rovers E; Gallenne T; Hendriks LJA; Visser T; Nijhuis R; Logtenberg T; de Kruif J; Gros P; Throsby M
Cancer Cell; 2018 May; 33(5):922-936.e10. PubMed ID: 29763625
[TBL] [Abstract][Full Text] [Related]
19. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
[TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
